Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2026 07:00 ET | Source: Ethyreal Bio, Inc.

Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease

– ETHY-001 targets the causal pathogenic mechanism underlying both conditions – – Patient-friendly subcutaneous administration with half-life extension for infrequent dosing – – First-in-human...